2025
The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer's disease
Zeiss C, Huttner A, Nairn A, Arnsten A, Datta D, Strittmatter S, Vander Wyk B, Duque A. The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer's disease. Journal Of Alzheimer’s Disease 2025, 104: 1243-1258. PMID: 40095666, DOI: 10.1177/13872877251323787.Peer-Reviewed Original ResearchAlzheimer's diseaseLate-onset Alzheimer's diseaseModel of late-onset Alzheimer's diseaseBraak stages III-IVDisruption of synaptic connectivityFormalin Fixed ParaffinAccumulation of senescence markersTau phosphorylationAmyloid-bFibrillar tauSenescence markersCo-morbiditiesPTau expressionLabile proteinBiomarker developmentStage III-IVSynaptic disruptionGlial fibrillary acidic proteinSenescence markers p16Fibrillary acidic proteinPredictive biomarkersFFPE tissuesMacaque modelAcidic proteinIII-IV
2024
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry M, Smith C, Halperin D, Brady J, Brennan B, Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer M, Eichenauer D, Hoppe R, Borchmann P, Fuchs M, Hartmann S, Eich H, Lo A, Skinnider B, Rauf M, Maghfoor I, Pinnix C, Milgrom S, Vega F, Alomari M, Collins G, Advani R, Metzger M, Wirth A, Tsang R, Smith S, Kelsey C, McKay P, Koenig J, Constine L, Sakthivel K, Plastaras J, Gao S, Al Rahbi N, Levis M, Sridhar A, Shah N, Osborne W, Chang I, Miall F, Mikhaeel G, Penn A, Volchkov E, Della Pepa R, Northend M, Opat S, Salvaris R, Tedjaseputra A, Palese M, Shankar A, Natkunam Y, Kelly K. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal Of Clinical Oncology 2024, 42: 2271-2280. PMID: 38531001, DOI: 10.1200/jco.23.01655.Peer-Reviewed Original ResearchNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalLymphocyte-predominant Hodgkin lymphomaInternational Prognostic ScoreImmunoarchitectural patternsOverall survivalHodgkin lymphomaPrognostic scoreSplenic involvementAssociated with worse progression-free survivalAssociated with progression-free survivalDe-escalation of therapyMedian Follow-UpAge of patientsProspective clinical trialHigh-risk patientsStage III-IVClinical risk factorsRisk of transformationStage I to IIB symptomsAdult patientsIII-IVActive surveillanceRare cancers
2019
Tubulointerstitial Infiltration of M2 Macrophages in Henoch‐Schönlein Purpura Nephritis Indicates the Presence of Glomerular Crescents and Bad Clinical Parameters
Kim J, Choi S, Lee K, Jeong H, Shin J, Lim B. Tubulointerstitial Infiltration of M2 Macrophages in Henoch‐Schönlein Purpura Nephritis Indicates the Presence of Glomerular Crescents and Bad Clinical Parameters. BioMed Research International 2019, 2019: 8579619. PMID: 30800680, PMCID: PMC6360621, DOI: 10.1155/2019/8579619.Peer-Reviewed Original ResearchConceptsClass III-IVChronic renal failureAssociated with chronic renal failureHenoch-Schonlein purpuraIII-IVISKDC classificationClinical parametersGlomerular crescentsInternational Study of Kidney DiseaseM2 macrophagesPresence of glomerular crescentsPresence of chronic renal failureAssociated with disease progressionInfiltration of M2 macrophagesInfiltration of M1Subtypes of macrophagesStudy of Kidney DiseaseTubulointerstitial infiltrationRenal involvementSystemic vasculitisISKDCRenal failureHistological featuresSevere manifestationsBorderline significance
1978
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Johnson R, Canellos G, Young R, Chabner B, DeVita V. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Journal Of The National Cancer Institute 1978, 62: 321-5. PMID: 580598.Peer-Reviewed Original ResearchConceptsTotal body irradiationTotal body irradiation patientsEvaluate new therapeutic approachesSurvival rateStage III-IVCandida sepsisDurable remissionsLymphocytic lymphomaBody irradiationMalignant lymphomaSevere granulocytopeniaMyeloproliferative disordersLate complicationsIII-IVChemotherapy complicationsInduction treatmentSurvival advantageNeurotoxic reactionsTherapeutic approachesLymphomaChemotherapyPatientsComplicationsRadiotherapySurvival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply